PureTech Health (LSE:PRTC) Change In Receivables : £0.50 Mil (TTM As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Change In Receivables?

PureTech Health's change in receivables for the quarter that ended in Dec. 2024 was £0.24 Mil. It means PureTech Health's Accounts Receivable declined by £0.24 Mil from Jun. 2024 to Dec. 2024 .

PureTech Health's change in receivables for the fiscal year that ended in Dec. 2024 was £0.50 Mil. It means PureTech Health's Accounts Receivable declined by £0.50 Mil from Dec. 2023 to Dec. 2024 .

PureTech Health's Accounts Receivable for the quarter that ended in Dec. 2024 was £1.20 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PureTech Health's Days Sales Outstanding for the six months ended in Dec. 2024 was 64.38.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PureTech Health's liquidation value for the six months ended in Dec. 2024 was £137.43 Mil.

PureTech Health Change In Receivables Historical Data

The historical data trend for PureTech Health's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Change In Receivables Chart

PureTech Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-0.39

-0.46

-6.35

7.70

0.50

PureTech Health Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-5.49	7.32	0.40	0.25	0.24

PureTech Health Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.50 Mil.

PureTech Health (LSE:PRTC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PureTech Health's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.204	/	3.413	*	91
=	64.38

2. In Ben Graham's calculation of liquidation value, PureTech Health's accounts receivable are only considered to be worth 75% of book value:

PureTech Health's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	290.54	-	154.009	+	0.75 * 1.204	+	0.5 * 0
=	137.43

PureTech Health Change In Receivables Related Terms

Thank you for viewing the detailed overview of PureTech Health's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (LSE:PRTC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

PRTC:USA PTCHF:USA PRTCl:UK 0VQ:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.